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Inhibition of tumor angiogenesis represents a promis-
ing new approach for the treatment of human can-
cers. It has remained unclear, however, whether
inhibition of tumor angiogenesis may also result in
impaired wound healing, a process thought to be
angiogenesis dependent. To determine the effects of
the angiogenesis inhibitor vasostatin, a 180 amino
acid calreticulin fragment, on wound healing at
tumor inhibiting doses, full-thickness wounds were
generated on the back of nude mice that were also
injected intradermally with CA46 Burkitt lymphoma
cells. Mice were treated with daily injections of vaso-
statin or vehicle control at a site between the wounds
and the transplanted tumor cells over 14 d. Vasostatin
potently inhibited tumor growth and signi®cantly
reduced tumor angiogenesis, as measured by com-
puter-assisted image analysis of CD31-stained tumor
sections. Moreover, vasostatin treatment resulted in
an increased fraction of mature tumor-associated
blood vessels. In contrast, no impairment of wound
healing was observed in vasostatin-treated mice, des-
pite a signi®cantly reduced vascularity of the wound
granulation tissue. Our results reveal a different sensi-
tivity of malignant tumor growth and physiologic
wound healing to inhibition of angiogenesis, and they
suggest that therapeutic inhibition of tumor angio-
genesis may be achieved without impairment of tissue
repair. Key words: calreticulin/cancer/endothelium/tissue
repair. J Invest Dermatol 117:1036±1041, 2001
T
he majority of current cancer treatments, including
polychemotherapy and radiation therapy, are asso-
ciated with serious adverse effects such as myelo-
depression, impaired tissue repair, and development of
tumor resistance to therapy. The inhibition of tumor
angiogenesis represents a promising new approach for the treatment
of human cancers, leading to tumor starvation and to repression of
metastatic spread (Hanahan and Folkman, 1996). Therapeutic
inhibition of tumor angiogenesis appears to be associated with a
relatively low rate of toxic adverse effects (Boehm et al, 1997). It has
remained unclear, however, whether antiangiogenic therapy at
tumor-relevant doses may also affect other angiogenesis-dependent
processes such as tissue repair. Cutaneous wound healing has been
thought to be critically dependent on the induction of angiogenesis.
Skin wounds are characterized by the formation of a richly
vascularized granulation tissue that supports the nutritional needs of
rapidly proliferating and migrating epidermal keratinocytes,
®broblasts, and leukocytes (Dvorak, 1986; Singer and Clark, 1999).
Naturally occurring angiogenesis inhibitors include thrombo-
spondin-1 (Iruela-Arispe et al, 1991), thrombospondin-2 (Volpert
et al, 1995), angiostatin, a fragment of plasminogen (O'Reilly et al,
1994), and endostatin, a fragment of collagen type XVIII (O'Reilly
et al, 1997). Vasostatin is a 180 amino acid NH2-terminal fragment
of human calreticulin (Pike et al, 1998). Calreticulin is found in the
sarcoplasmic reticulum of skeletal muscle cells and is involved in the
regulation of calcium storage (Michalak et al, 1992). Both vasostatin
and calreticulin inhibit endothelial proliferation in vitro and suppress
tumor growth and angiogenesis in vivo (Tosato et al, 1994; Pike et al,
1998; 1999). To investigate whether angiogenesis inhibition at
tumor-inhibiting doses might impair cutaneous wound healing, we
evaluated full-thickness wounds in tumor-bearing mice treated
with the endogenous angiogenesis inhibitor vasostatin. We
implanted CA46 Burkitt lymphoma cells into the back skin of
nude mice and also generated full-thickness skin wounds on the
contralateral side in the same animals. Mice were treated with
vasostatin or vehicle control, and tumor growth and wound closure
were closely evaluated.
We demonstrate that vasostatin potently inhibited tumor growth
and angiogenesis of CA46 Burkitt lymphomas without any
detectable effect on the rate of wound closure, despite signi®cantly
reduced vascularity of the wound granulation tissue. Our results
reveal a different sensitivity of malignant tumor growth versus
physiologic tissue repair to inhibition of angiogenesis, and they
suggest that the therapeutic inhibition of angiogenesis at tumor-
inhibiting doses is not necessarily associated with impaired tissue
repair.
MATERIALS AND METHODS
Tumorigenesis assay Human CA46 Burkitt lymphoma cells (Sgadari
et al, 1996) were cultured in RPMI 1640 medium supplemented with
12% fetal bovine serum, 2 mmol per l L-glutamine, and 5 mg per ml
gentamicin (all purchased from Life Technologies, Rockville, MD).
2 3 107 cells in 100 ml phosphate-buffered saline were injected
intradermally into the right side of the back of 8-wk-old female Swiss
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nu/nu mice. Tumor sizes were determined by measuring the largest and
the smallest tumor diameter, using a digital caliper (Streit et al, 1999).
Tumor volumes were calculated using the formula: volume = 4/3 3 p
3 (1
2
smaller diameter)2 3 1
2
larger diameter. Tumors were harvested
from at least three animals for each treatment group and for each time
point and were embedded in OCT compound (Sakura, Torrance, CA)
and snap frozen in liquid nitrogen.
Wound healing studies Six hours after the ®rst injection of either
vasostatin or buffer (30 h after tumor injection into the contralateral
side), mice were anesthetized with a single intraperitoneal injection of
avertin (0.5 mg per 10 g body weight 2,2,2-tribromoethanol in 2.5%
tert-amyl alcohol; Sigma). A full-thickness wound was created on the left
side of the back of each mouse, using a 6 mm biopsy punch (Acuderm,
Ft. Lauderdale, FL). Wound closure was monitored daily for 14 d in at
least 10 mice for each time point by covering each wound with a
transparent plastic sheet and marking the wound areas on the plastic
sheet. Wound area measurements were performed on scanned
transparencies, using the IP-LAB software (Scanalytics, Fairfax, VA) as
described previously (Streit et al, 2000). Wound closure was expressed as
the percentage of the initial wound area. Wounds were harvested from
at least three animals per treatment and time point on days 3, 6, and 14.
An area of 7±8 mm in diameter, including the complete epithelial
margin of the wounds and the muscle fascia, was excised and cut in half.
Wound specimens were either frozen in OCT compound or ®xed for
48 h in 4% paraformaldehyde in phosphate-buffered saline and then
embedded in paraf®n. All experiments were repeated at least twice.
Vasostatin treatment One day after intradermal injection of tumor
cells, 100 mg vasostatin (n = 16) or vehicle control (n = 16; 0.9% saline,
50 mg per ml human albumin, 5 mg per ml mannitol) were injected
subcutaneously in close vicinity to the site of tumor cell inoculation.
Subcutaneous injections were continued daily in between the tumors and
the wounds over 2 wk. Recombinant vasostatin was produced as
recently described (Pike et al, 1998). The puri®ed protein was tested for
endotoxin by the Limulus Amebocyte Lysate kinetic-QCL assay (Bio
Whittaker, Walkersville, MD) and was found to contain less than 5 EU
per 10 mg protein.
Immunohistochemistry Immunohistochemistry was performed on
6 mm frozen or paraf®n sections of wounds and tumors as described
previously (Detmar et al, 1997). Vessels were stained with a monoclonal
antibody against the endothelial junction molecule CD31 (Albelda et al,
1991) (dilution 1:50; Pharmingen, San Diego, CA). Perivascular smooth
muscle cells and pericytes were stained with an antihuman a-smooth
muscle actin (a-SMA) antibody (dilution 1:100; clone 14A, Dako,
Denmark). Masson's trichrome staining was performed on paraf®n
sections according to standard techniques (Prophet et al, 1992). The
maturation status of blood vessels was assessed by double
immuno¯uorescence staining for CD31 and a-SMA, using secondary
antibodies labeled with either Texas Red or ¯uorescein isothiocyanate
(1:50; Jackson ImmunoResearch Laboratory, West Grove, PA) as
described previously (Benjamin et al, 1998). The vessel maturation index
was calculated as the percentage of CD31-positive vessels that were
associated with a-SMA-positive periendothelial cells. A total of at least
400 blood vessels were evaluated in each treatment group. Nuclear
staining was performed with 20 mg per ml Hoechst bisbenzimide
(Sigma). Endothelial cell proliferation was studied by intraperitoneal
injection of mice with 5-bromo-deoxyuridine (BrdU; 250 mg per kg of
body weight; Sigma) 2 h prior to sacri®ce, followed by double
immuno¯uorescence staining with anti-BrdU (Pharmingen) and anti-
CD31 antibodies. Sections were mounted in Mowiol (Calbiochem, La
Jolla, CA) and ¯uorescence and conventional light microscopy were
performed using a Nikon E-600 microscope (Nikon, Melville, NY).
Computer-assisted morphometric analysis of tumor and wound
vessels Wound and tumor sections were obtained from three mice of
each experimental group at 3, 6, and 14 d after wounding. Six micron
frozen sections were stained with a monoclonal rat antimouse CD31
antibody and were analyzed using a Nikon E-600 microscope. Digital
images were captured with a Spot digital camera (Diagnostic Instruments,
Sterling Heights, MI), and morphometric analyses were performed using
the IP-LAB software. Three different ®elds per section were examined at
603 magni®cation and the number of vessels per mm2, the average
vessel size, the vessel size distribution, and the percentage of tumor area
or granulation tissue area covered by blood vessels were determined as
described previously (Streit et al, 1999). Furthermore, combined CD31
and BrdU immuno¯uorescence stains of wound and tumor sections,
obtained at 14 d after initiation of treatment, were analyzed using a
Nikon E-600 microscope. Digital images were captured with a Spot
digital camera and were examined at 103 magni®cation. The number of
Figure 1. Vasostatin inhibits tumor growth. Treatment of CA46
Burkitt lymphomas with vasostatin (®lled bars) signi®cantly inhibited
tumor growth, compared with control-treated tumors (open bars). Data
represent mean 6 SEM; **p < 0.01.
Figure 2. Vasostatin inhibits tumor angiogenesis. Comparable
tumor architecture and cellular morphology in the viable areas of control
(A) and vasostatin-treated (B) CA46 Burkitt lymphomas 14 d after
intradermal injection. Hematoxylin and eosin stain. Immunostaining with
an anti-CD31 antibody demonstrated rare®cation of tumor blood vessels
in vasostatin-treated tumors (D), compared with control tumors (C).
Double immuno¯uorescence staining for CD31 (green) and a-SMA
(red) demonstrates increased numbers of blood vessels associated with a-
SMA positive mural cells (yellow, arrowheads) in vasostatin-treated tumors
(F) compared to control tumors (E). Scale bars: 250 mm.
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proliferating endothelial cells was determined by counting the number of
BrdU- and CD31-positive cells at 603 magni®cation as described
previously (Streit et al, 2000). The two-sided unpaired Student's t test
was used for statistical analyses.
RESULTS
Vasostatin inhibits tumor growth and angiogenesis of CA46
Burkitt lymphomas Fourteen days after intradermal injection
of CA46 Burkitt lymphoma cells, detectable tumor formation was
found in 81% of the mice that were treated with vehicle control but
only in 44% of vasostatin-treated mice. Treatment with vasostatin
potently inhibited tumor growth with a reduction of the average
tumor size by 79% (12.6 6 6.3 mm3) compared with control-
treated tumors (60.2 6 18.4 mm3) at 6 d after tumor cell injection.
Fourteen days after tumor cell injection, tumor growth was
signi®cantly inhibited (p < 0.01) by more than 90% in the
vasostatin-treated group (40.5 6 23.2 mm3) compared with the
control group (455.4 6 120.4 mm3) (Fig 1). Histologic analysis of
viable tumor areas did not reveal major differences of the tumor
architecture or cellular morphology between control and
vasostatin-treated tumors (Fig 2A, B). Staining for the
endothelial junction molecule CD31, however, demonstrated
rare®cation of tumor-associated blood vessels after vasostatin
treatment (Fig 2C, D).
To investigate the effects of vasostatin on the maturation status of
the tumor vasculature, we simultaneously visualized endothelial
cells and mural cells (smooth muscle cells and pericytes) by
differential immuno¯uorescence staining for CD31 and a-SMA
(Benjamin et al, 1999). We found an increased number of vessels
associated with a-SMA-positive cells in vasostatin-treated tumors
(Fig 2F) compared with control-treated tumors (Fig 2E).
Quantitative evaluation revealed that the vessel maturation index,
de®ned as the percentage of CD31-positive vessels associated with
a-SMA-positive periendothelial cells, was signi®cantly higher in
vasostatin-treated tumors (83.5% 6 7.1%) than in control tumors
(55.2% 6 11.6%; p < 0.01).
Computer-assisted morphometric analyses of CD31-stained
tumor sections revealed a signi®cantly decreased vascular density
in vasostatin-treated tumors with a more than 30% reduction in
vessel numbers on day 6 (p < 0.01) and a more than 40% reduction
at day 14 after tumor transplantation (p < 0.001) (Fig 3A). In
contrast, the average size of tumor vessels was unaffected by
vasostatin treatment (Fig 3B) and no major changes in the size
distribution of tumor-associated blood vessels were found
(Fig 3D). Overall, the relative tumor area covered by blood
vessels was decreased by more than 30% on day 6 and by more than
40% (p < 0.001) on day 14 in vasostatin-treated tumors (Fig 3C).
Vasostatin treatment does not impair wound healing
Excisional full-thickness wounds were created on the backs of
tumor-bearing 8-wk-old mice at 6 h after the ®rst injection of
vasostatin or vehicle control. Twenty-four hours post wounding,
wounds were covered with a dry scab that remained adherent for
5±7 d in all mice. After 3 d, the wound areas were reduced to
approximately 50% of the original size (Fig 4). Daily wound area
measurements did not reveal any signi®cant difference in the rate of
wound closure between vasostatin-treated mice (58.1% 6 11% of
the original wound area at day 3, 44.1% 6 12% at day 6, and
3.6% 6 1.1% at day 14) or control-treated mice (54.8% 6 12.9%
at day 3, 49.0% 6 9.7% at day 6, and 4.1% 6 2.1% at day 14)
(Fig 4) and complete wound closure occurred within 14 d in both
groups. Comparable results were obtained in three independent
experiments. Invasion of granulation tissue from the wound
margins into the wound bed was already observed 3 d after
injury and on day 6 the wound bed was completely ®lled with
Figure 3. Diminished tumour vascularization
after vasostatin treatment. Computer-assisted
morphometric analysis of CD31-stained tumor
sections revealed a signi®cantly reduced
microvascular density in vasostatin-treated tumors
(A). No signi®cant difference in the average size
(B) and the size distribution (D) of blood vessels
was found between the two experimental groups.
A decrease in the relative tumor area covered by
blood vessels was detected in vasostatin-treated
tumors (C). CD31-stained blood vessels were
evaluated in corresponding 103 ®elds in sections
of at least three different tumors per time point.
Data are expressed as mean 6 SEM; **p < 0.01,
***p < 0.001.
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granulation tissue in both control and vasostatin-treated mice
(Fig 5A, B). After 14 d, both control-treated wounds and
vasostatin-treated wounds (Fig 5C, D) were completely covered
by a multilayered neo-epidermis.
Vasostatin inhibits wound angiogenesis Vasostatin treatment
resulted in a signi®cant reduction of the vessel density in the
granulation tissue compared to control-treated wounds (Fig 5E,
F). Furthermore, treatment with vasostatin led to a 48.1%
reduction of the number of proliferating endothelial cells in
tumors and to a 52.4% inhibition of proliferating endothelial cells in
wounds at day 14 (Fig 5G, H). We observed a more than 20%
decrease of vessel number on days 3 (p < 0.01) and 14 (p < 0.001)
and a more than 15% reduction after 6 d (p < 0.05) (Fig 6A). The
average vessel size was slightly smaller in the granulation tissue of
vasostatin-treated mice (Fig 6B), and no major changes in the size
distribution of blood vessels were found (Fig 6D). The relative area
of granulation tissue that was covered by blood vessels, however,
re¯ecting changes in both vessel number and size, was signi®cantly
reduced following vasostatin treatment (Fig 6C), with a more than
35% reduction on days 3 (p < 0.01) and 6 (p < 0.05) and a more
than 25% reduction on day 14 (p < 0.05).
DISCUSSION
In order to grow beyond a minimal size and to metastasize, tumors
need to induce the growth of new blood vessels (angiogenesis),
providing a lifeline for tumor sustenance and waste disposal
(Hanahan and Folkman, 1996). Inhibition of tumor angiogenesis
represents a new approach for the treatment of cancers and might
potentially avoid the development of tumor cell resistance and the
occurrence of some of the adverse effects observed with
polychemotherapy (Boehm et al, 1997). Because antiangiogenic
therapies for the treatment of human cancers will most probably be
administered over prolonged time periods, it is of considerable
clinical importance to evaluate whether long-term inhibition of
angiogenesis may also inhibit other physiologic or pathologic
processes that are thought to be angiogenesis dependent. In
particular, it remains to be established whether systemic inhibition
of angiogenesis might result in impaired tissue repair as it occurs in
ischemic heart disease or in cutaneous wound healing. Although a
small number of studies have aimed at characterizing the effects of
distinct antiangiogenic regimens on wound healing (Klein et al,
1999; Berger et al, 2000; Bloch et al, 2000; Streit et al, 2000; Wood
et al, 2000), the results have been controversial. In particular, it has
remained unclear whether some of the observed inhibition of
wound healing might have been the result of effects of angiogenesis
inhibitors on nonendothelial cells such as ®broblasts, leading to
delayed granulation tissue formation (Streit et al, 2000) or to
inhibiting effects on the activity of matrix metalloproteinases (Klein
et al, 1999; Streit et al, 2000). Moreover, con¯icting results have
been reported regarding the effects of the angiogenesis inhibitor
endostatin on the vascularity of wound granulation tissue (Berger
et al, 2000; Bloch et al, 2000), and the criteria for the evaluation of
wound healing have not been well de®ned. Importantly, none of
these previous studies directly investigated the effects of angio-
genesis inhibition on wound healing at tumor-inhibiting doses
within the same animals.
In this study, we examined the effects of the angiogenesis
inhibitor vasostatin on wound healing in tumor-bearing mice.
Figure 4. Vasostatin does not impair would closure. Comparable
closure rates of full-thickness wounds in mice treated with vasostatin
(®lled circles; n = 16) or vehicle control (open squares; n = 16). Complete
wound closure occurred after 14 d in both groups. Wound closure is
expressed as a percentage of the original wound area and data are
expressed as mean 6 SD. Data shown are representative of three
independent experiments.
Figure 5. Reduced vascularity of granulation tissue in vasostatin-
treatment mice. Comparable formation of granulation tissue in
vasostatin-treated (B) full-thickness wounds at 6 d after wounding,
compared to control-treated wounds (A). Hematoxylin and eosin stain.
Control-treated wounds (C) and vasostatin-treated wounds (D) show
typical organization and maturation of granulation tissue 14 d after
wounding. Hematoxylin and eosin stains. CD31 immunostains depict
diminished vascularization in the granulation tissue of vasostatin-treated
wounds (F) compared to control-treated wounds (E) at 14 d post
wounding. Pronounced inhibition of vascular endothelial cell
proliferation and neovascularization in granulation tissue of vasostatin-
treated wounds (H) at 14 d post wounding compared with numerous
proliferating endothelial cells in control-treated wounds (G) at 14 d post
wounding. Immuno¯uorescence staining demonstrates CD31-stained
blood vessels (red), BrdU-labeled proliferating nonendothelial cells
(green), and CD31/BrdU double-stained proliferating vascular
endothelial cells (yellow, arrowheads). Scale bars: 250 mm.
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Vasostatin treatment potently reduced the tumor-forming ef®-
ciency of CA46 Burkitt lymphoma cells and signi®cantly inhibited
malignant tumor growth. These data are in accordance with the
previously reported antitumoral activity of vasostatin (Pike et al,
1998; Yao et al, 2000) and they con®rm that the doses used in our
experiments were indeed tumor suppressive. Vasostatin treatment
also resulted in a pronounced reduction of the vascular density of
tumors whereas the average size of tumor-associated blood vessels
was only slightly reduced. It is of interest that we found a
signi®cantly increased percentage of a-SMA-positive tumor vessels
after vasostatin treatment, indicating that vasostatin induced a
higher degree of vessel maturation, similar to that found in slowly
developing tissues or under physiologic conditions in normal skin
(Benjamin et al, 1998). Pericytes are closely associated with
endothelial cells in the microvasculature (Beck and D'Amore,
1997) and it has been suggested that blood vessels with pericyte
coverage have a diminished ability to sprout and to form new
capillaries (Darland and D'Amore, 1999). The reduced vascular
density observed in tumors after vasostatin treatment re¯ects these
blood vessels' reduced ability to form vascular sprouts as a result of
an increase in their maturation (Pettersson et al, 2000).
Importantly, treatment with tumor-inhibiting doses of vasostatin
(100 mg per d) did not result in delayed closure of full-thickness
skin wounds in tumor-bearing mice. The model of full-thickness
wounds induced in mouse skin represents a well-established
experimental system for studies of wound healing and has revealed
important insights into the distinct roles of a number of growth
factors in tissue repair (Werner et al, 1992; Frank et al, 1995;
Forsberg et al, 1996; Hubner et al, 1996; Beer et al, 1997; Munz et
al, 1999; Bloch et al, 2000; Streit et al, 2000). Both control and
vasostatin-treated mice showed complete wound closure within
14 d after injury, and no major macroscopic differences of the
wound healing process were detected over a 14 d period. Although
wound contraction plays an important role during the ®rst few days
after wounding, full-thickness wounds in mouse skin are also
characterized by ingrowth of a ®broblast-rich granulation tissue
from the deep wound margins into the wound area and by
prominent neovascularization of the granulation tissue (Clark,
1993). Histologic analysis did not detect major delays of granulation
tissue formation under vasostatin treatment. When we studied the
number of proliferating endothelial cells in both wounds and
tumors by combined immuno¯uorescence stains for CD31 and
BrdU, however, we found a reduced number of proliferating
endothelial cells in tumors and in wounds treated with vasostatin.
Furthermore, computer-assisted image analysis of wound sections
stained for the endothelial junction molecule CD31 (Dejana et al,
1995) revealed that vasostatin treatment resulted in signi®cantly
reduced vascularity of the granulation tissue. The reduced
vascularity was still observed 14 d post wounding when the
wound closure was completed and when the granulation tissue had
undergone maturation and organization (Singer and Clark, 1999).
Therefore, our ®ndings indicate that inhibition of wound
angiogenesis does not necessarily result in impaired wound healing.
Taken together, our results suggest that malignant tumor growth
is more sensitive to angiogenesis inhibition than physiologic tissue
repair. This may be explained, in part, by our ®ndings that tumor
tissue was much less vascularized than wound granulation tissue. In
fact, control-treated wounds showed a 3-fold higher vascular
density than control-treated CA46 Burkitt lymphomas in this
study. Although it remains to be established whether these ®ndings
apply to the majority of malignant tumors, our previous studies in
transplanted SCC-13 or A431 squamous cell carcinomas also
detected vascular densities that were markedly lower than those
found here in wound granulation tissue (Streit et al, 1999; Detmar
Figure 6. Reduced vascularity of wound
granulation tissue after vasostatin treatment.
Computer-assisted morphometric analysis of
CD31-stained wound sections revealed a
signi®cantly reduced microvascular density in
vasostatin-treated wounds (®lled bars), compared
with control-treated wounds (open bars) (A). No
signi®cant differences were detected in the average
size (B) or the size distribution (D) of vessels
between the two experimental groups. The
relative area of granulation tissue covered by
blood vessels was signi®cantly decreased in
vasostatin-treated mice (C). CD31-stained blood
vessels were evaluated in three different 103 ®elds
in sections obtained from at least three different
wounds per time point. Data are expressed as
mean 6 SEM. *p < 0.05, **p < 0.01, ***p
< 0.001.
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et al, 2000). Our results demonstrate that angiogenesis in wound
repair, a process essential to survival, is more redundant than
angiogenesis in tumors, which appear to be critically dependent on
their blood supply. These ®ndings may have implications for the
development of antiangiogenic cancer therapies and indicate that
different thresholds may apply to ef®cient angiogenesis inhibition in
tumors and in nonmalignant tissues (Eberhard et al, 2000).
In summary, we show that the angiogenesis inhibitor vasostatin
potently inhibited the tumor growth and angiogenesis of CA46
Burkitt lymphomas transplanted into nude mice without major
impairment of wound healing. Our results suggest a different
sensitivity of tumors and wounds to inhibition of angiogenesis,
most probably related to the more pronounced and more
redundant vascularization of the wound granulation tissue. They
also indicate that ef®cient antiangiogenic therapy of malignant
tumors can be achieved without impairment of tissue repair.
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